Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Diltiazem (1) ·
Duloxetine (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Phenelzine (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1) ·
Verapamil (1)
brand:
None (1) ·
Anafranil (1) ·
Aurorix (1) ·
Calan, Calan SR, Verelan, Verelan PM, Isoptin SR (1) ·
Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)
uses:
None (18) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"' (1) ·
'"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"' (1)
starting dose:
None (18) ·
25 mg (1) ·
ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) ·
IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
None (17) ·
3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"' (1) ·
3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"' (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
None (17) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' (1) ·
~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (17) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data; alternative antihypertensives generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; labetalol/nifedipine generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 21 results in range #1 to #21.